Related Experiment Videos
[Systemic side effects in immunotherapy of allergic diseases--a comparative study]
M Wekkeli1, A Rosenkranz, G Hippamann
1Dermatologisches und pädiatrisches Allergieambulatorium, Wien.
Wiener Klinische Wochenschrift
|October 13, 1989
Summary
Systemic side effects (SSE) from specific immunotherapy for allergic diseases remain low, with current standards reflecting historical findings. Persistent antihistamine use and reduced allergen dosage contribute to this safety profile.
Area of Science:
- Allergy and Immunology
- Pharmacology
- Clinical Medicine
Context:
- Specific immunotherapy (SI) for allergic diseases involves repeated allergen exposure to induce tolerance.
- Systemic side effects (SSE) are a critical safety concern in SI, influencing treatment protocols.
- A historical benchmark of 0.4% SSE per injection was established by the study authors in 1987.
Purpose:
- To evaluate and compare current data on SSE from SI over the last decade against a historical standard.
- To identify factors contributing to the low incidence of SSE in contemporary SI practices.
- To assess the safety profile of various SI preparations.
Summary:
- A review of 99 publications over 10 years indicates a continued low rate of SSE in SI for allergic diseases.
- This low rate aligns with and upholds the 0.4% SSE benchmark established by the authors in 1987.
- Key factors for minimizing SSE include consistent antihistamine premedication and limiting allergen dosage to 50,000 SQ units.
Impact:
- The findings reinforce the safety and efficacy of current SI protocols for managing allergic diseases.
- This study provides evidence supporting the continued use of established safety measures in SI.
- The data aids clinicians in optimizing SI treatments for improved patient outcomes and safety.